Frequently Asked Questions
SCiStar study participants must be 18 to 69 years of age and able to begin screening within 37 days of a cervical spinal cord injury in the neck region. They also must be able to receive AST-OPC1 agent between 21 and 42 days following injury. Additional eligibility criteria apply.
AST-OPC1 consists of neural cells known as oligodendrocyte progenitor cells, which are produced from human embryonic stem cells. AST-OPC1 was previously tested in the world’s first human clinical trial of a stem cell derived product.
AST-OPC1 was previously tested in a clinical study of people completely paralyzed from the waist down.
The previous clinical study of AST-OPC1 was designed to evaluate the safety of a single low dose. No clinical benefit was expected or reported from that study.
Lab studies have shown the cells in AST-OPC1 promote partial repair of damaged spinal cord tissue and some improvement in the ability of some animals to move their back and/or front legs.
The study sponsor, Asterias Biotherapeutics, will pay the costs of non-routine medical treatments conducted as part of this study. The costs of your routine medical care will be billed to you or to your health insurance company or government insurance program in the usual way.
Throughout the SCiStar study, participants and caregivers will receive detailed information about the status of their own health as well as updates on important overall study findings.
The SCiStar study for spinal cord injury is sponsored by Asterias Biotherapeutics, Inc., a leader in the emerging field of regenerative medicine. Asterias is focused on developing therapies to treat diseases or serious injuries in areas with high unmet medical needs or inadequate therapies.
We encourage participants to discuss the SCiStar study with their family members, but ultimately, the decision to disclose participation is up to them.